Coeptis Therapeutics (NASDAQ:ZSQR) Sees Unusually-High Trading Volume – Here’s Why

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) saw unusually-strong trading volume on Wednesday . Approximately 214,714 shares traded hands during mid-day trading, an increase of 156% from the previous session’s volume of 84,030 shares.The stock last traded at $9.87 and had previously closed at $9.47.

Coeptis Therapeutics Trading Up 4.4%

The stock has a market cap of $508.64 million, a PE ratio of -3.92 and a beta of -0.09. The company’s 50-day moving average price is $12.10 and its 200 day moving average price is $13.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The business had revenue of $0.11 million during the quarter.

Institutional Trading of Coeptis Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ZSQR. Geode Capital Management LLC lifted its position in Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares during the last quarter. State Street Corp raised its stake in shares of Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after acquiring an additional 6,962 shares during the period. Marshall Wace LLP acquired a new position in shares of Coeptis Therapeutics in the 4th quarter worth approximately $259,000. Yorkville Advisors Global LP acquired a new position in shares of Coeptis Therapeutics in the 3rd quarter worth approximately $140,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after purchasing an additional 2,500 shares during the period. 13.88% of the stock is currently owned by hedge funds and other institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.